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Abstract: Infant ALL displays distinct biologic and clinical features with a poor prognosis. The CD10-
negative immunophenotype of infant ALL is a hallmark and provides a predictable signature of MLL 
rearrangement. While CD10 negativity reflects an earlier stage of B-cell development, complete IgH 
gene rearrangements (VDJH), found in almost half of the patients, show more mature IgH status. 
Discordance between immunophenotype and genotype of infant ALL suggests an aberrant process in 
immunophenotypic steps of differentiation or a secondary down-regulation of CD10 expression. In this 
study, CD10-negative infant ALL with MLL/AF4, CD10-positive infant ALL with germ-line MLL, CD10-
positive pre-B ALL cell line, infant AML (M5) with MLL/AF9 and pediatric AML (M2) with AML1/ETO 
were analyzed for VDJH status and methylation of CD10 gene promoters. Three of the four infant ALL 
samples showed complete rearrangements of the VDJH gene with productive joints. Bisulfite 
sequencing of CD10 type 1 and 2 promoters showed that more than 84% of the CpG dinucleotides 
identified were methylated in all three CD10-negative infant ALL samples with MLL/AF4. The CpG 
dinucleotides distributed in the clusters of putative Sp1-binding sites and functionally active 
regulatory regions of the promoters were fully methylated. In contrast, none of the CpG dinucleotides 
were methylated in the CD10-positive ALL samples. Structural evidence of dense methylation in the 
CD10 gene promoter suggested that methylated transcription factor binding sites contributing to CD10 





TABLE I. Clinical Features, CD10 expression and MLL Rearrangements of the Leukemic Samples






0 m 15 m (R) 11 m 7 m 8 m 5 y
112,000 2,200 54,700 38,920 11,100 7,120
Sex female female male male female male female
t(4;11) t(4;11) t(4;11) t(9;11) t(8;21)normal hypodiploid
MLL/AF4 MLL/AF4 MLL/AF4 MLL/AF9 AML1/ETO－
<1 1.3 0.2 42.8 99.4 <1 <1
iALL, infant ALL; CL, cell line; iAML, infant AML; pAML, pediatric AML; sCD10, surface CD10; m, months; y, years; R, relapse;




Table (No Excel Files!  Submit as MS Word)
TABLE II. VDJH Rearrangement Status of Infant ALL
VDJH status
Allele 1 Allele 2
iALL-1 VH 6-1/DH 6-19/JH 4
(out of frame/nonproductive)
VH 2-26/DH 3-3/JH 6
(in frame/productive)
iALL-2 VH 1-02/DH 3-22/JH 4
(out of frame/nonproductive)
VH 2-26/DH 3-3/JH 6
(in frame/productive)
iALL-3 ND ND
iALL-4 VH 5/DH nd/JH nd
(out of frame/nonproductive)
VH 1-03/DH 1-26/JH 5
(in frame/productive)
iALL, infant ALL; ND, not detected; nd, not defined
TABLE III. Number of CpGs and Methylation Status of ALL and AML 





Analyzed 44 48 36 45 41 34 33
7 0 0 45 41 34 31
37 48 36 0 0 0 2
84 100 100 0 0 0 6.1





Analyzed 15 17 12 16 14 9 9
0 0 0 16 14 9 9
15 17 12 0 0 0 0
100 100 100 0 0 0 0
Type 1 and 2 regulatory region (66) 





Analyzed 29 31 24 29 27 25 24
7 0 0 29 27 25 22
22 31 24 0 0 0 2
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ABSTRACT 
Infant ALL displays distinct biologic and clinical features with a poor prognosis. The 
CD10-negative immunophenotype of infant ALL is a hallmark and provides a predictable 
signature of MLL rearrangement. While CD10 negativity reflects an earlier stage of B-cell 
development, complete IgH gene rearrangements (VDJH), found in almost half of the patients, 
show more mature IgH status. Discordance between immunophenotype and genotype of infant 
ALL suggests an aberrant process in immunophenotypic steps of differentiation or a secondary 
down-regulation of CD10 expression. In this study, CD10-negative infant ALL with MLL/AF4, 
CD10-positive infant ALL with germ-line MLL, CD10-positive pre-B ALL cell line, infant 
AML (M5) with MLL/AF9 and pediatric AML (M2) with AML1/ETO were analyzed for VDJH 
status and methylation of CD10 gene promoters. Three of the four infant ALL samples showed 
complete rearrangements of the VDJH gene with productive joints. Bisulfite sequencing of 
CD10 type 1 and 2 promoters showed that more than 84% of the CpG dinucleotides identified 
were methylated in all three CD10-negative infant ALL samples with MLL/AF4. The CpG 
dinucleotides distributed in the clusters of putative Sp1-binding sites and functionally active 
regulatory regions of the promoters were fully methylated. In contrast, none of the CpG 
 3 
dinucleotides were methylated in the CD10-positive ALL samples. Structural evidence of dense 
methylation in the CD10 gene promoter suggested that methylated transcription factor binding 
sites contributing to CD10 silencing as an epigenetic mechanism.  
 4 
INTRODUCTION 
   Infant acute leukemia occurs within the first year of life and displays distinct biologic and 
clinical features with a poor prognosis. 
1-4
 Seventy to 90% of patients harbor rearrangements of 
the mixed-lineage leukemia (MLL) gene at the chromosomal region 11q23. 
5, 6
 The acute 
lymphoblastic leukemia (ALL) subtype of infant acute leukemia predominantly includes the 
t(4;11)(q21;q23) region with the MLL/AF4 fusion gene, followed by the t(11;19)(q23;p13) 
region with the MLL/ENL fusion gene and the t(9;11)(p22;q23) region with the MLL/AF9 
fusion gene. 
7, 8
 Recent gene expression profiling studies indicate that MLL-rearranged 
(MLL-R) ALLs are arrested at an early lymphoid progenitor stage of development. 
9, 10
 Among 
these highly distinct expression patterns in MLL-R, a total lack of CD10 expression is a 
hallmark and provides a predictable signature of MLL rearrangements. 
9, 11
 
   CD10, the neutral endopeptidase 24.11, is a regulator of B-cell growth and proliferation. 
12
 
The enzyme degrades a number of bioactive peptides with various functions that depend on the 
cell type or tissue of origin. CD10 is expressed in a biphasic pattern that correlates with specific 
stages of B cell development. CD10 is detected on precursor B (pro- and pre-B) cells and lymph 
node germinal center B cells but is not detected on lymphoid progenitor cells, early pro-B cells, 
 5 
mature B cells (naïve B-cells and mantle cells) or plasma cells. 
13
 This biphasic pattern is 
generally maintained in malignant counterparts. 
13 
   Immunoglobulin (Ig) gene rearrangements are regarded as a molecular fingerprint of B cell 
development. 
14
 CD10 is believed to be expressed during the first stages of Ig heavy-chain (IgH) 
rearrangement and can be co-expressed with surface -VpreB or -5 pre-BCR. 15 Several lines 
of evidence indicate a high frequency of complete IgH rearrangements (VDJH) in 
CD10-negative pro-B ALL. 
16
 Ig gene rearrangement patterns were related to the presence and 
type of MLL rearrangement but not to the age at diagnosis or to ALL-CD10 expression. 
16, 17
 
Discordance between the genotype and the immunophenotype of infant ALL with respect to 
cellular maturity suggested an aberrant process in the steps of immunophenotypic differentiation 
or a secondary down-regulation of CD10 expression associated with MLL rearrangements. 
   Methylation of promoter-associated cytosine-guanine (CpG) islands is an epigenetic 
modification of DNA and has been associated with gene silencing and malignant transformation. 
18, 19
 An inverse correlation was previously observed between methylation of the CD10 promoter 
and CD10 expression in adult 
20
 and pediatric ALL 
21
 as well as in human prostate cancer. 
22
 
However, data on the frequency of methylation in the various types of ALL, particularly in 
 6 
infant ALL with MLL-R, remain scarce. We therefore performed methylation analysis of the 
entire promoter region of the CD10 gene in infant ALL to investigate epigenetic mechanisms 
responsible for CD10 negativity. We describe dense methylation of the CD10 promoter with 
particular emphasis on the methylation of transcription factor binding sites within the CD10 
promoter (type 1 and 2 regulatory regions) in CD10-negative MLL/AF4 infant ALL carrying a 
productive rearrangement of the VDJH allele. 
 
MATERIALS AND METHODS 
 
Cell Samples 
   Peripheral blood (PB) or bone marrow (BM) samples from MLL/AF4 infant leukemia (3 
samples), acute myeloid leukemia (AML) (2 samples, AML1/ETO and MLL/AF9, respectively) 
and a sample of infant pre-B ALL (MLL-germline, MLL-G) were obtained after informed 
parental consent and with approval of the Ethics Committee of the Kanazawa University 
Hospital. The pre-B ALL cell line (HAL-01) was from RIKEN Bank (Tsukuba, Ibaraki, Japan). 
Mononuclear cells were isolated from PB or BM samples by Ficoll-Paque density gradient 
 7 
centrifugation. DNA was extracted and purified according to the manufacturer’s instructions 
using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany). 
The immunophenotype of leukemic cells was assessed by flow cytometry using a dual-laser 
FACS Calibur (Becton Dickinson, San Diego, CA, USA). The resulting data were analyzed 
using the CELL Quest software (Becton Dickinson). Immunophenotypic subclassification was 
done according to the guidelines of the European Group for the Immunological Characterization 
of Leukemias (EGIL): Pro-B ALL, CD19+/CD10-/cytoplasmic (cy) IgM-/surface (s) IgM-; 
common ALL, CD19+/CD10+/cy IgM-/s IgM- and Pre-B ALL, CD19+/CD10+/cy IgM+/s 
IgM-. Criteria for immunophenotypic marker positivity were: expression on >20%, or >10% of 
blasts for cell surface and cytoplasmic markers, respectively. 
 
Detection of Rearranged Leukemia-associated Genes 
   The presence of t(4;11)(q21;q23) with the MLL/AF4 fusion gene, t(9;11)(p22;q23) with the 
MLL/AF9 fusion gene and t(8;21)(q22;q22) with the AML1/ETO fusion gene was demonstrated 
by one or more of the following methods: metaphase cytogenetic analysis, polymerase chain 
reaction (PCR) with reverse transcription (RT-PCR) and fluorescence in situ hybridization 
 8 
(FISH) as part of the diagnostic work-up. 
 
Polymerase Chain Reaction (PCR) and Sequence Analysis of IgH Gene Rearrangements 
   PCR amplification of IgH-VDJ rearrangements was performed in a Thermocycler 
(GeneAmp PCR system 9700, Applied Biosystems) using a series of seven VH family FR1 
consensus primers and a JH consensus primer by modification of a method previously described. 
23
 Clonal PCR products were purified using QIAquick gel extraction kits (QIAGEN, Hilden, 
Germany), directly sequenced using the BigDye-Terminator v3.1 cycle sequencing kit and were 
analyzed on a 3100 sequencer (Applied Biosystems). VH, DH, JH segments and their family 
members were identified with the closest matching known human germ line genes using the 
IGBlast search (http://www.ncbi.nlm.nih.gov/igblast/, National Center for Biotechnology 
Information, Bethesda, MD). The criteria used for DH gene determination were: a minimal 
homology of six matches in a row or seven matches interrupted by one mismatch. 
 
Bisulfite Modification of DNA, PCR Amplification, and Sequence Analyses of the CD10 
Promoter Regions 
 9 
   All methylation studies were done by bisulfite modification of DNA which converts all 
unmethylated cytosine-phosphate-guanosine (CpG) sites to uracil-phosphate-guanosine (UpG), 
leaving methylated CpGs intact. Bisulfite treatment of genomic DNA was done using 
MethylEasy Xceed (Human Genetic Signatures, North Ryde, Australia). The DNA was then 
amplified with the following gene-specific primers: Type 1-1, sense 5’- 
TTTATAGGGGAGAGATGGAG-3’; antisense 5’- ACCAAAAAAAAAAACAATTCC- 3’; 
Type 1-2, sense 5’- TTTTTGGTTTTGTAGTGGT-3’; antisense 5’- 
CAATCAAACTTCACCACTTA-3’; Type 2-1, sense 5’- TTYGGTTTTAGTTTGGAGTT-3’; 
antisense 5’- CCCTTTAAACCTTTCTCCCT-3’; Type 2-2, sense 5’- 
TGTGGGTGTGGGTTGGAGGGATG-3’; antisense 5’- CCCTCCCCATGCCCATCCCAC-3’. 
Following sequencing of the amplified DNA, methylated CpGs were identified by visual 
inspection of the sequencing traces in the electropherograms and by comparison with 
sequencing traces of the CD10 gene sequence relative to the reference GenBank sequence 





Clinical Features, Immunophenotype and MLL Rearrangements of the Leukemic Samples 
   The clinical features of seven samples and the characteristics of their leukemic cells are 
described in Table I. Four of the five samples (<12 months of age) of infant leukemia (iALL-1 
to -4, and iAML) and a pediatric AML (pAML) sample (5 years of age) were studied at 
diagnosis. A case with congenital ALL was analyzed at day 1 of age for initial diagnosis 
(iALL-1) and at 15 months of age for relapse (iALL-2). A cell line (Pre-B CL) established from 
a 17-year-old female with pre-B ALL was also studied. Three of the four infant ALL samples 
(iALL-1 to -3) were t(4;11)-positive ALL with the MLL/AF4 fusion gene and one sample 
(iALL-4) showed a normal karyotype. The iAML and pAML samples were t(9;11)-positive with 
the MLL/AF9 fusion gene and t(8;21)-positive with the AML1/ETO fusion gene, respectively. 
CD10 expression, determined by the flow cytometric immunophenotyping, was negative 
(<20%) in all three MLL/AF4-positive ALLs (iALL-1 to -3) with a pro-B ALL 
immunophenotype (CD19+/CD34+/cyIgM-/sIgM-). In contrast, MLL-G ALLs (iALL-4 and 




IgH Gene Rearrangements (VDJH) in Infant ALL 
   Sequence analyses of PCR-amplified VDJH segments are summarized in Table II. In two 
CD10-negative infant ALL (iALL-1 and -2) and a CD10-posivitive infant ALL (iALL-4), two 
major clonal VDJH rearrangements were identified, in which each sequence contained either an 
out-of-frame joining (a nonproductive rearrangement) or an in-frame joining without a stop 
codon (a productive rearrangement). In iALL-3, clonal PCR products were not detected 
following repeated amplification, indicating that the IgH genes remained germ line or that there 
was only DJ joining. These recombination processes were consistent with a hierarchical order of 
IgH gene rearrangements in normal B precursor cells. 
14
 In addition, in the case with congenital 
leukemia, biclonality of the leukemic cells was shown by a difference in the usage of VH and DH 
gene family members in nonproductive rearrangements determined at diagnosis (iALL-1) and 
relapse (iALL-2). These results indicated that CD10 negativity was not correlated with the 
developmental status of IgH gene rearrangements in infant ALL. 
 
Methylation of the CD10 Promoter in Infant ALL 
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   Figure 1 contains electropherograms of base sequences, from nt -211 to nt -177, for two 
representative samples (i-ALL-2 and pre-B CL) with bisulfite treatment. Cytosine residues other 
than CpG dinucleotides were all converted to thymine, whereas methylated cytosine residues in 
CpG dinucleotides were retained as cytosine, indicating that bisulfite treatment was completed. 
The CD10 gene promoter contains two separate regulatory regions that control the transcription 
of 5’ alternatively spliced CD10 transcripts. 24 The type 1 regulatory region contains the exon 1 
sequence within nt -821 to nt -326 relative to the major transcription initiation site at the 
beginning of exon 2. The type 2 regulatory region spans the sequence from nt -326 to nt +105 
(Fig. 2). 
25, 26
 In addition, three functionally active transcription factor binding sites, designated 
as regions I to III, have been identified in the type 2 regulatory region (Fig. 2B). 
25
 A total of 66 
CpG dinucleotides are present within these two regulatory regions (24 in the type 1 regulatory 
region and 42 in the type 2 regulatory region) (Fig. 2 and Table III). Mapping of the CpG 
dinucleotides showed that they were densely distributed within the 3’-half portion of the type 1 
regulatory region and over the entire type 2 regulatory region (Fig. 2B). At least 33 of these 66 
CpG dinucleotides were successfully analyzed by bisulfite sequencing (Table III, Fig. 2B). We 
quantified CpG methylation as the methylated CpG content (%) in a single gene by showing the 
 13 
number of CpG methylation present in the CD10 promoter region. This analysis showed that 
more than 84% of the identified CpG dinucleotides in all three CD10-negative infant ALL with 
MLL/AF4 were methylated. Comparison of the two regulatory regions revealed no difference in 
methylation frequency. In contrast, none of the CpG dinucleotides were methylated in the 
CD10-positive ALL (iALL-4 and Pre-B CL) and only 2 of the CpG dinucleotides were 
methylated in pAML samples (Table III, Fig. 2B).  
   Figure 3 illustrates the CD10 promoter methylation status and transcription factor binding 
sites in the representative iALL-2 sample. 
27
 The 5’ UTR exon 1 sequence contained multiple 
putative PU.1 binding sites, consensus ets-binding motifs and a cluster of four potential 
Sp1-binding sites (Fig. 3A). The CpG dinucleotides within the Sp1-binding sites, as well as in 
the surrounding sites were highly methylated. In the type 2 regulatory region (Fig 3B), 31 of the 
42 CpG dinucleotides were analyzed and all 31 were methylated. Notably, three putative 
Sp1-binding sites, as well as functionally active transcription factor binding sites in regions I to 
III, contained 12 (39%) of these methylated CpG dinucleotides. These results indicated that both 
type 1 and 2 regulatory regions in the CD 10 gene promoter were highly methylated in 
CD10-negative infant ALL with MLL/AF4 and provided structural evidence of dense 
 14 
methylation of the transcription factor binding sites.  
 
DISCUSSION 
   We have demonstrated dense methylation patterns in both type 1 and 2 regulatory regions of 
the CD10 promoter in CD10-negative MLL/AF4 infant ALL bearing a productive, rearranged 
VDJH allele. In addition, we are the first to describe the precise methylated sites within the 
CD10 gene promoter. 
   Two separate regulatory regions have been identified in the CD10 gene promoter. 
25-27
 The 
type 1 and 2 regulatory regions share common features characterized by the presence of multiple 
transcription initiation sites and the absence of classic TATA boxes and consensus initiator 
elements. The purine-rich type 1 regulatory region includes the 5’ UTR exon 1 sequence with 
multiple putative PU.1 binding sites and consensus ets-binding motifs. 
27, 28
 The distribution 
map of CpG dinucleotides showed a concentration of methylated CpG dinucleotides within the 
3’-half portion of the type 1 regulatory region (Fig 2A), in which a cluster of four potential 
Sp1-binding sites is located (Fig 3A). Clustering of Sp1-binding sites and their cooperative 




Therefore, Sp1-binding sites observed in exon 1 of the CD10 gene are anticipated to contribute 
to type 1 promoter activity. Indeed, a factor(s) immunologically related to Sp1 specifically binds 
to the most upstream GC-rich sequence (ggtggg) and is required for optimal promoter activity. 
26
 Bisulfite sequencing revealed that the CpG dinucleotides in the putative Sp1-binding sites 
were almost all methylated in three samples of infant ALL with MLL/AF4. The sequence 
upstream of exon 1 that contains multiple putative PU.1 sites and ets-binding motifs also 
showed a positive influence on type 1 CD10 promoter activity. 
27
 However, it is unlikely that 
methylation is involved in the action of these regulatory elements since there are no CpG 
dinucleotides in the consensus sites. 
   The GC-rich type 2 regulatory region identified in the intron upstream of exon 2 
27
 contains 
numerous CpG dinucleotides (Fig 2). Strikingly, 31 CpG dinucleotides were distributed in the 
type 2 regulatory region and all were methylated in a sample of infant ALL (iALL-2) (Fig 2). 
Such high frequency of methylation was consistently seen in an additional two samples of 
CD10-negative ALL (Fig 2). The CD 10 type 2 regulatory region contains multiple putative 
Sp1-binding sites, a potential consensus retinoblastoma control element (RCE) and an inverted 
CCAAT box. 
25, 27
 Upregulation of Sp1-mediated transcription by retinoblastoma protein 
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through the RCE has been reported. 
29
 Recently, three functionally active transcription factor 
binding sites, designated as regions I to III, have been identified in the type 2 regulatory region. 
25
 CBF/NF-Y was shown to bind the inverted CCAAT box in region I and is responsible for 
tissue-specific CD10 expression. 
25
 Bisulfite sequencing indicated complete methylation of the 
CpG dinucleotides in the three putative Sp1-binding sites and within regions I to III in infant 
ALL with MLL/AF4 (Fig 3B). Specific methyl-CpG dinucleotides within the promoter may 
inhibit trans-factors that preferentially bind to sequences containing CpG dinucleotides by 
limiting DNA access to the factors or by conformational alteration of DNA structure or they 
may act as a guide for methyl-CpG-binding proteins (MeCP-1 and MeCP-2) that modulate 
transcriptional activity. 
30-32
 Thus, structural evidence of dense methylation in two regulatory 
regions of the promoter suggests that methylated transcription factor binding sites contribute to 
CD10 silencing as an epigenetic mechanism. Since our study contained no MLL/ENL or 
MLL/AF9 ALL samples, extended analyses including MLL-R subtypes are required to specify 
MLL-R involvement in methylation of the CD10 promoter. 
   Three types of CD10 transcripts, types 1, 2A and 2B, have been identified resulting from 
alternative splicing of 5’ untranslated regions; the type 1 regulatory region promotes type 1 
 17 
transcripts from exon 1 and the type 2 regulatory region promotes types 2A and 2B transcripts 
initiated within exon 2 in a tissue-specific manner. 
27
 Type 2 transcripts are more abundant than 
type 1 transcripts in a variety of cell types, while some CD10-positive pre-B cell ALL cell lines 
have also been shown to contain high levels of type 1 transcripts. 
27
 Although the relative 
abundance of type1 and type 2 transcripts was not examined in our clinical samples, 
hypermethylation of both of the regulatory regions is consistent with a total lack of CD10 
expression in infant ALL with MLL/AF4. 
   Taylor et al. 
13
 have shown that the CD10 promoter region is consistently not methylated in 
normal lymphocytes at early and late stages of maturation regardless of the CD10 expression 
level, while in B-cell malignancies methylation of the CD10 promoter is common at specific 
stages of maturation and is frequently associated with absence of CD10 expression. These data 
suggest that the biphasic pattern of CD10 expression in normal differentiation of B cells is 
controlled by tissue- and stage-specific regulatory mechanisms other than DNA methylation. 
However, CD10 methylation plays a role in lymphoid malignancies by silencing CD10 
expression. Further investigations are required for complete elucidation of the role of 
methylation in CD10 expression because epigenetic modulation involves not only DNA 
 18 




   In conclusion, our results show structural evidence of DNA promoter methylation 
suggesting a contribution to CD10 silencing as an epigenetic mechanism. Functional analyses 
such as transfection of MLL fusion genes are required to confirm the precise involvement of 
MLL-R in methylation. Further investigation of epigenetic network interactions associated with 
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Fig. 1. Electropherograms of base sequences with or without bisulfite treatment.  
A. Reference sequence of the CD10 promoter region, from nt -211 to nt -177 (GenBank 
accession number: X 79438). The CpG dinucleotides are underlined. 
B. Electropherogram of iALL-2 without bisulfite treatment. 
C. Electropherogram of iALL-2 with bisulfate treatment.  
D. Electropherogram of pre-B CL with bisulfate treatment. 
 
Fig. 2. Methylation status of the CD10 gene promoter region in leukemic cells. 
A. Structural illustration of the 5’ UTR exon 1 and exon 2 of the CD10 gene promoter region. 
The arrow delineates the major transcription initiation site (+1)  
B. Distribution maps of the CpG dinucleotides and their methylation status. Closed and open 
circles indicate methylated and unmethylated CpG dinucleotides, respectively. The vertical 
bars represent the position of CpG dinucleotides. 
 
Fig. 3. CD10 promoter methylation status and transcription binding sites in iALL-2. 
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A. Putative binding sites for the ets, PU.1 and Sp1 transcription factors within the 5’ UTR 
proximal to exon 1. The dashed box delineates the type 1 regulatory region. Methylated CpG 
dinucleotides are indicated as in Fig. 1. 
B. Transcription factor binding sites within the type 2 regulatory region. RCE and inv. CCAAT 
indicate a potential consensus retinoblastoma control element and an inverted CCAAT box, 
respectively. 
To Review Officials: 
Point-by-point responses to the comments of the reviewers are as follows. 
1. In the abstract, at the bottom line the authors state "None or few of the CpG 
dinucleotides were methylated." It is unclear what they mean by few. This should be 
much more specific in an abstract. 
 
A1: “A few of the methylated CpG dinucleotides” indicate 2 of the methylated 
CpG observed in a pAML case as shown in Figure 2. However, as indicated by the 
reviewer, the description in the abstract should be concisely focusing on the 
methylation status of ALL. Thus, we have amended the description in the abstract 
as follows: “In contrast, none of the CpG dinucleotides were methylated in the 
CD10-positive ALL samples”, on page 2, line 16. 
Following the amendment, we have changed the description in the results as 
follows: “In contrast, none of the CpG dinucleotides were methylated in the 
CD10-positive ALL (iALL-4 and Pre-B CL) and only 2 of the CpG dinucleotides 
were methylated in pAML samples (Table III, Fig. 2B)”, on page 13, line 4. 
 
2. On page 4 fourth line from the bottom, the authors state that "The enzyme is a cell 
surface aminopeptidase". It is not an aminopeptidase, but an endopeptidase. 
 
A2: We have amended the description of this enzyme as follows: “The enzyme 
degrades a number of bioactive peptides with various functions that depend on the 
cell type or tissue of origin”, on page 4, line 13. 
 
*Response to Reviewers
3. On page 10, the authors state that CD10 was absent in all three MLL/AF4 positive 
ALL's. They do not indicate how this was determined and the methodology used to 
make this statement. 
 
A3: We have amended the description of CD10 expression as follows: “CD10 
expression, determined by the flow cytometric immunophenotyping, was negative 
(<20%) in all three MLL/AF4-positive ALLs (iALL-1 to -3) with a pro-B ALL 
immunophenotype (CD19+/CD34+/cyIgM-/sIgM-)”, on page 10, line 12. 
